Results of Phase Ib Non-Muscle Invasive Bladder Cancer (“NMIBC”) Clinical Study Demonstrate a 66% Complete Response (“CR”) at the Therapeutic Dose (0.70 mg/cm2) 360 Days Post Treatment Toronto, Ontario –April 2, 2019 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations intended to safely and effectively destroy various cancers is pleased to report that patient six, enrolled and treated in the recently completed Phase Ib NMIBC Clinical Study (“Study”), has demonstrated a CR with no tumour recurrence, progression or presence of NMIBC disease at the 360 day clinical and cystoscopy assessment. The Study’s purpose was to evaluate TLD-1433, Theralase’s lead PDC, for the primary endpoint of safety and tolerability, a secondary endpoint of pharmacokinetics (movement and exit of drug within tissue) and exploratory endpoint of … Read More

Toronto, Ontario – March 26, 2019 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated PhotoDynamic Compounds (“PDC”) and their associated drug formulations intended to safely and effectively destroy various cancers is pleased to announce that the results of the Phase Ib clinical study will be presented at the 17th International Photodynamic Association (“IPA”) World Congress, to be held in Cambridge, Massachusetts from June 28th to July 4th, 2019. IPA has been bringing together researchers and clinicians in all fields of PhotoDynamic Therapy (“PDT”) and PhotoDiagnosis (“PD”) since 1986. Every two years, the IPA organizes a conference to foster scientific development and contribute to clinical practice, ultimately capturing the current status of the field. This year, Lother Lilge, Ph.D., Professor of Medical Biophysics at the University of Toronto, an esteemed PDT expert and a … Read More

Toronto, Ontario – March 4, 2019 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations intended to safely and effectively destroy various cancers, announced today that it has been granted allowance for a United States patent to issue later this year for destroying cancer cells with X-ray activated PDCs. The new patent to issue later this year is entitled, “Photodynamic Compounds and Methods for Activating Them Using Ionizing Radiation and/or Other Electromagnetic Radiation for Therapy and/or Diagnostics” Arkady Mandel, M.D., Ph.D., D.Sc., Chief Scientific Officer of Theralase® and the lead inventor of the technology stated that, “In 2019, the Company plans to commence a Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC“) clinical study, which if successful may lead to commercialization of this technology in Canada, the United States … Read More

Toronto, Ontario – February 28, 2019 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations intended to safely and effectively destroy various cancers has been named third place on the 2019 TSX Venture 50TM in the Clean Technology & Life Sciences sector amongst all TSX Venture Exchange listed companies. The ranking is comprised of ten companies from each of five industry sectors, selected based on three equally weighted criteria: market capitalization growth, share price appreciation and trading volume amount. Theralase is a previous winner of the 2015 TSX Venture 50TM. Dr. Shawn Shirazi, Ph.D., Chief Executive Officer – Drug Division, Theralase® stated that, “Theralase’s achievement of third place in the 2019 TSX Venture 50TM top performing companies is a strong indication of the value that the Company … Read More

Toronto, Ontario – February 25, 2019 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations intended to safely and effectively destroy various cancers is pleased to announce the appointment of Shawn Shirazi, Ph.D., to the role of CEO of Theralase’s Drug Division (“CEO-Drug”) and Kipton Lade, B.Sc., M.Sc., MBA., to the role of Chief Executive Officer (“CEO”) of Theralase’s Device Division (“CEO-Device”). Shawn Shirazi, Ph.D. Pharmacology obtained his B.Sc. in Chemistry from York University (Toronto, Ontario, Canada) and a M.Sc. and Ph.D. in Pharmacology from the University of Ottawa (Ottawa, Ontario, Canada). Dr. Shirazi brings over 20 years of hands-on experience in: pharmaceutical drug formulation and development, clinical trial management, Good Manufacturing Practices (“GMP”) international drug manufacture, international regulatory guidelines and quality assurance in GMP drug manufacture. He … Read More

Toronto, Ontario – January 31, 2019 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations intended to safely and effectively destroy various cancers reports that patient five, enrolled and treated in the recently completed Phase Ib Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study (“Study”), has demonstrated no tumour recurrence or presence of disease at the 360 day clinical and cystoscopy assessment. The Study’s purpose was to evaluate TLD-1433, Theralase’s lead PDC, for the primary endpoint of safety and tolerability, secondary endpoint of pharmacokinetics (movement and exit of drug within tissue) and exploratory endpoint of efficacy, primarily at 90 days and secondarily at 180 days post treatment. The Study was successfully completed with patient five and six demonstrating achievement of the primary, secondary and exploratory endpoints. … Read More

Toronto, Ontario – January 30, 2019 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations intended to safely and effectively destroy various cancers reports that patient six, enrolled and treated in the recently completed Phase Ib Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study (“Study”), has demonstrated no tumour recurrence or presence of disease at the 270 day clinical and cystoscopy assessment. The Study’s purpose was to evaluate TLD-1433, Theralase’s lead PDC, for the primary endpoint of safety and tolerability, secondary endpoint of pharmacokinetics (movement and exit of drug within tissue) and exploratory endpoint of efficacy, primarily at 90 days and secondarily at 180 days post treatment. The Study was successfully completed with patient five and six demonstrating achievement of the primary, secondary and exploratory endpoints. … Read More

Toronto, Ontario – January 9, 2019 Theralase Technologies Inc. (“Theralase®” or “Company”) (TSXV: TLT) (OTCQB: TLTFF) is pleased to announce that it has closed its previously announced non-brokered privateplacement offering (“Offering”) of units (“Units”). On closing, the Corporation issued an aggregate of 4,095,157 Units at a price of $0.35 per Unit for aggregate gross proceeds of approximately $1,433,305. Each Unit consisted of one common share of the Company (“Common Share”) and one common share purchase warrant (“Warrant”). Each Warrant entitles the holder to acquire an additional Common Shareat an exercise price of $0.50 per share for a period of 24 months following the date of issuance. In connection with the Offering, the Company paid a finder’s fee of $210, and issued 300 finder’s warrants. Each finder’s warrant is exercisable into one Common Share at an exercise price of $0.50 per share for a period of 24 months after the closing … Read More

Toronto, Ontario – December 10, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”)(TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drugformulations, intended to safely and effectively destroy various cancers, announced today that Health Canada has granted the Company Investigational Testing Authorization (“ITA”) approval to utilize its patent pending TLC-3000 Photo Dynamic Therapy (“PDT”) Laser System, in conjunction with its Clinical Trial Application (“CTA”) approved lead PDC, TLD-1433, to commence enrolling and treating patients in a Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study (“Study II”), subject to submitting a Clinical Trial Site Information Form and receipt of their respective Research Ethics Board (“REB”) approval for each Canadian oncology location that will conduct Study II. The TLC-3000 PDT Laser System delivers green laser light (525 nm), while simultaneously monitoring the laser light to … Read More

Rutherrin® mediated Photo Dynamic Therapy improves cancer specific immune responses by switching the so called “Don’t eat me” signal that cancer cells use to trick the immune system into the “Eat me” signal on treated human glioblastoma cells, a relevant cell model of Glioblastoma Multiforme. Toronto, Ontario – November 30, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations, used to safely and effectively destroy various cancers, announced today that Theralase’s Rutherrin® Photo Dynamic Therapy (“PDT”) has been shown to increase its efficacy in cancer treatments, inducing a cancer specific immune response, by switching the so-called “Don’t eat me” signal to an “Eat me” signal on treated human glioblastoma cells. This switch in cellular signalling improves the uptake of treated cancer cells by immune … Read More